ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
8 hedge funds and large institutions have $1.03M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
12% less call options, than puts
Call options by funds: $266K | Put options by funds: $301K
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
38% less capital invested
Capital invested by funds: $1.67M → $1.03M (-$634K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
+$120K |
| 2 |
GHAM
Gilman Hill Asset Management
New Canaan,
Connecticut
|
+$120K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$43.9K |
| 4 |
VF
Virtu Financial
New York
|
+$14.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$319K |
| 2 |
Jane Street
New York
|
-$301K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$6.57K |
| 4 |
Morgan Stanley
New York
|
-$3.79K |
ZBIO Hedge Fund Activity: Q3 2017 in Review
8 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q3 2017, worth a combined $1.03M — down 38% from $1.67M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ZBIO positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Ballentine Partners, opening a new position worth an estimated $120K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $319K sold.
- 8 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q3 2017, up from 7 in Q2 2017.
- Funds reported $1.03M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q3 2017, down 38% quarter-over-quarter.
- 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q3 2017 and 1 closed out, a net change of +1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q3 2017 was Ballentine Partners, an estimated $120K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q3 2017 was Susquehanna International Group, an estimated $319K sold.
Based on aggregated 13F filings for Q3 2017.